| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.011 | 1 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.011 | 1 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.0027 | 1 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | 0.0016 | 1 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.0015 | 1 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.002 | 1 |